Introduction to XII Updating Course of Antimicrobials and Infectious Diseases (2025)

SARS-CoV-2 infection: etiopathogenesis, clinical picture, current therapeutic options – the author’s observations

2021

Currently, the scenario of a self-contained disappearance of the epidemic (as it was in the case of SARS) is no longer taken into consideration, whilst the SARS-CoV-2 virus will stay with us forever, similarly to other coronaviruses or flu. It is quite likely that periodical exacerbations of the epidemics – their growth and decrease – depend on many factors, which comprise, among others, the approval of the restrictions by the society or the manner in the epidemiological supervision is carried out and whether it is consistent. We must be ready for about 18–24 months of a high activity of COVID-19 with periodic active hot spots in many world regions. This requires efficient health services and the access to efficacious medication. Without an effective prophylactic vaccine, it seems that we will not be able to prevent the spread of the pandemic

A review on SARS-CoV-2: the origin, taxonomy, transmission, diagnosis, clinical manifestations, treatment and prophylaxis

GSC Biological and Pharmaceutical Sciences, 2020

SARS-CoV-2: Virology, epidemiology, immunology and vaccine development

Biologicals, 2020

SARS-CoV-2: generalidades, origen y avances en el tratamiento

Gaceta Medica De Mexico, 2021

SARS-CoV-2 infection: a global outbreak and its implication on public health

Bulletin of the National Research Centre, 2021

Options of Treatment in SARS-CoV-2 Infections

Pneumologia

Starting December 2019, in China, the SARS-CoV-2 infection became a local health issue, but its high infectiveness quickly turned it into a pandemic, to be declared an epidemiological emergency of international concern less than two months from identifying the first cases. Despite tremendous efforts aimed at discovering new drug classes that would slow down or stop the evolution of the COVID-19 disease and curb the number of severe cases and related complications, there is no specific antiviral treatment to date. The only efficient measure proved to be the prophylaxis, through vaccination.

Epidemiology, Treatment and Microbiological Surveillance of SARS-CoV-2

Annual Research & Review in Biology

Coronaviruses (CoV) belong to Coronaviridiae family that cause deadly diseases in humans or animals. These viruses are enveloped and have single stranded positive-sense large RNA genome. Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) causes deadly pandemic coronavirus disease-2019 (COVID-19) in humans. It is affecting every aspect of humans’ daily life. The symptoms of COVID-19 include fever, loss of smell, shortness of breath, cough, muscles pain, chest pain, and kidney failure that occurs in severe conditions. The virus has spread throughout the world. In India, the estimated number of infected people is more than 1.5 lakh with less fatality rate 2.87% on May 27, 2020 as per the Ministry of Health and Family Welfare data. The studies suggest that virus has been considered descended from the previous viruses as severe acute respiratory syndrome corona virus (SARS-CoV), Middle East respiratory syndrome virus (MERS) human and bat corona viruses. Currently, vaccine deve...

SARS-CoV-2 will continue to circulate in the human population: an opinion from the point of view of the virus-host relationship

Inflammation Research, 2020

A comprehensive review about SARS-CoV-2

Future Virology, 2020

The coronavirus disease (COVID-19) was first identified in China, December 2019. Since then, it has spread the length and breadth of the world at an unprecedented, alarming rate. Severe acute respiratory syndrome coronavirus (SARS-CoV)-2, which causes COVID-19, has much in common with its closest homologs, SARS-CoV and Middle East respiratory syndrome-CoV. The virus–host interaction of SARS-CoV-2 uses the same receptor, ACE2, which is similar to that of SARS-CoV, which spreads through the respiratory tract. Patients with COVID-19 report symptoms including mild-to-severe fever, cough and fatigue; very few patients report gastrointestinal infections. There are no specific antiviral strategies. A few strong medications are under investigation, so we have to focus on proposals which ought to be taken to forestall this infection in a living host.

Kalın Ünüvar G, Rello J, Alp E. Effectiveness of COVID-19 Vaccines and Antiviral Therapies in the Era of SARS-CoV-2 Variants. Erciyes Med J 2023; 45(1): 1–7.

Erciyes Medical Journal, 2023

Since December 2019, the respiratory infection coronavirus disease 2019 (COVID-19) has been responsible for a major pandemic. Several mutations and variants have emerged and been seen throughout the pandemic. They eventually spread to various continents and nations. The most effective method of preventing illnesses from the past till the present has been vaccination. As a result of the advancement of vaccinations, numerous nations have begun immunizing global target groups. From the start of COVID-19 to the present, there aren't many possibilities for therapy. Data indicate that the rapid evolution and transmission of SARS-CoV-2 variants poses a danger to the effectiveness of currently available medications. As a result, the COVID-19 pandemic brought to light a serious public health issue that had an impact on everyone in the world. Along with the pandemic's rapid speed, new targeted vaccinations and medical therapies have reduced fears to some extent. Clinical phase studies are still being conducted in various areas because it is evident that the initial antiviral medications approved for use in the treatment of COVID-19 are ineffective in severe cases. Anti-vaccination, however, is one of the most serious barriers to vaccination, which is thought to be vital in the prevention of illnesses. Lack of information, incorrect information, and misguided religious beliefs can all contribute to anti-vaccination. With the advent of SARS-CoV-2 variants, we review the literature to provide an up-to-date overview of the features and efficacy of antiviral therapy and vaccines.